Time course of platelet activation and von Willebrand factor in patients with non-valvular atrial fibrillation after ischemic stroke - Evaluation of prognostic determinants

Circulation Journal

Volumn 71, Issue 3, 2007, Pages 321-326

  Yip, Hon Kan ^a   Lai, Shung Lon ^a   Lan, Min Yu ^a   Chang, Wen Neng ^a   Liu, Josef S ^a   Kao, Yi Fen ^a   Chang, Yung Yee ^a   Lu, Cheng Hsien ^a   Chen, Wei Hsi ^a   Lin, Hung Hseng ^a   Liou, Chia Wei ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Brain infarct volume; Ischemic stroke; Non valvular atrial fibrillation; Platelet activation

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; VON WILLEBRAND FACTOR; WARFARIN;

ANTIGEN EXPRESSION; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RANKIN SCALE; THROMBOCYTE ACTIVATION;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; SURVIVAL RATE; TIME; VON WILLEBRAND FACTOR;

EID: 33947169848     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.321     Document Type: Article

References (29)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of millennium: Triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-1369.
2. Tsang TSM, Petty GW, Barnes ME, O'Fallon WM, Bailey KR, Wiebers DO, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population control in Rochester, Minnesota: Changes over three decades. J Am Coll Cardiol 2003; 42: 93-100.
3. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
4. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death: The Framingham Heart Study. Circulation 1995; 92: 835-841.
5. Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
6. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998; 128: 639-647.
7. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. reduce flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999; 12: 1080-1087.
8. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31: 822-827.
9. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GYH, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999; 30: 2547-2553.
10. Conway DSG, Pearce LA, Chin BSP, Hart RG, Lip GYH. Plasma von Willebrand factors and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors. Circulation 2002; 106: 1962-1967.
11. Hart RG, Halperin JL. Atrial fibrillation and stroke: Concepts and controversies. Stroke 2001; 32: 803-808.
12. Fisher M, Levine P, Fullerton A, Forsberg A, Duffy C, Hoogasian J, et al. Markers proteins of platelet activation in patients with cerebrovascular disease. Arch Neurol 1982; 39: 692-695.
13. Fisher M, Francis R. Altered coagulation in cerebral ischemia: Platelet, thrombin, and plasmin activity. Arch Neurol 1990; 47: 1075-1079.
14. Joseph R, D'Andrea G, Oster S, Welch K. Whole blood platelet function in acute ischemic stroke: Importance of dense body secretion and effects of antithrombotic agents. Stroke 1989; 20: 38-44.
15. Inoue H, Nozawa T, Iwasa A, Okumura K, Lee JD, Shimizu A, et al. Accumulation of risk factors increases of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006; 70: 651-656.
16. Conway DSG, Heeringa J, Van der Kuip DAM, Chin BSP, Hofman A, Witteman JCM, et al. Atrial fibrillation and the prothrombotic state in the elderly: The Rotterdam study. Stroke 2003; 34: 413-417.
17. Conway DSG, Pearce LA, Chin BSP, Hart RG, Lip GYH. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-3145.
18. Yip HK, Liou CW, Chang HW, Lan MY, Liu JS, Chen MC. Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 2005; 20: 120-128.
19. van Kooten F, Ciabattoni G, Koudstaal PJ, Dippel DWJ, Patrono C. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke 1999; 30: 546-549.
20. Yip HK, Chen SS, Liu JS, Chang HW, Kao YF, Lan MY, et al. Serial changes in platelet activation in patients after ischemic stroke: Role of pharmacodynamic modulation. Stroke 2004; 35: 1683-1687.
21. Trip MD, Cats VM, Van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554.
22. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcomes, and treatment in subtypes of ischemic stroke: The German Stroke Data Bank. Stroke 2001; 32: 2559-2566.
23. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607.
24. Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570-2574.
25. Goto S, Sakai H, Goto M, Ono M, Ikeda Y, Handa S, et al. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 1999; 99: 608-613.
26. Blann AD, Lip GYH, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: A comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-1080.
27. Adjusted-dose warfarin versus low-density, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
28. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrhematic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
29. Yamagami H, Kitagawa K, Ohtsuki T, Matsumoto M, Hori M. Embolic cerebral infarction caused by intraluminal thrombus in the carotid siphon successfully treated with combination of anticoagulant and antiplatelet drugs. Circ J 2005; 69: 1147-1149.